KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

AbCellera Biologics (ABCL) Depreciation Expense (2022 - 2023)

Historic Depreciation Expense for AbCellera Biologics (ABCL) over the last 2 years, with Q4 2023 value amounting to $3.9 million.

  • AbCellera Biologics' Depreciation Expense rose 3988.52% to $3.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $12.9 million, marking a year-over-year increase of 4352.47%. This contributed to the annual value of $12.5 million for FY2024, which is 205.47% down from last year.
  • As of Q4 2023, AbCellera Biologics' Depreciation Expense stood at $3.9 million, which was up 3988.52% from $3.1 million recorded in Q3 2023.
  • AbCellera Biologics' Depreciation Expense's 5-year high stood at $3.9 million during Q4 2023, with a 5-year trough of $1.4 million in Q1 2022.